Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
Evaxion expands collaboration with MSD for preclinical vaccine candidates
Contract Type
agreement
CopenhagenBiotechnologyHealth CareArtificial IntelligenceDescription
Evaxion Biotech A/S has expanded its collaboration with MSD by entering into an option and license agreement for two preclinical vaccine candidates, EVX-B2 and EVX-B3. The agreement carries significant value for Evaxion and includes an upfront payment of $3.2 million and up to $10 million in 2025, contingent upon MSD exercising its option to license either one or both candidates. Additionally, Evaxion is eligible for development, regulatory and sales milestone payments with a potential value of up to $592 million per product, as well as royalties on net sales.